Real-time multiple mutation detection technology for drug resistant mutations in TB to be introduced

Seegene Inc., a leading developer of multiplex molecular diagnostic technologies and tests, today announced that it will introduce Quantplex(TM) MTB/MDR/XDR Detection, a real time test that detects Mycobacterium tuberculosis and resistance mutations associated with multiple drug resistant (MDR) and extensively drug resistant (XDR) forms of M. tuberculosis at the 2012 American Association of Clinical Chemistry (AACC) annual meeting, held in Los Angeles, from July 17-19. This new test is based on powerful enhancements to the company's TOCE(TM) technology, called Cleavage Site Specific Extension (TOCE-CSSE), that enables high multiplex mutation detection of disease.